NCT07850310 A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
| NCT ID | NCT07850310 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2026-10-20 |
| Primary Completion | 2027-12-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 132 participants in total. It began in 2026-10-20 with a primary completion date of 2027-12-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people. This trial will help researchers learn about the safety of MK-8644 and if participants tolerate it. Tolerate means participants will receive MK-8644 in the trial unless they need to stop it due to health problems.
Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a BMI between 18 and 36 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. * Has a history of cancer. * Has a history of significant multiple and/or severe allergies. * Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, tuberculosis, or HIV.
Contact & Investigator
Medical Director
STUDY DIRECTOR
Merck Sharp & Dohme LLC
Frequently Asked Questions
Who can join the NCT07850310 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07850310 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07850310 currently recruiting?
Yes, NCT07850310 is actively recruiting participants. Contact the research team at Trialsites@merck.com for enrollment information.
Where is the NCT07850310 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT07850310 clinical trial?
NCT07850310 is sponsored by Merck Sharp & Dohme LLC. The principal investigator is Medical Director at Merck Sharp & Dohme LLC. The trial plans to enroll 132 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.